ruxolitinib phosphate · Incyte Corp · NDA 217180
Jakafi Xr
Earliest generic entry, as listed · earliest of 5 marketed strengths
17 Jul 2034
Blocked by patent: US 11337927.
Listed patents · 53 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11337927 | — | 17 Jul 2034 |
| US 10874616 | — | 14 May 2034 |
| US 11576864 | — | 14 May 2034 |
| US 11576865 | — | 14 May 2034 |
| US 11896717 | — | 14 May 2034 |
| US 11337927 | use U-3230 | 17 Jan 2034 |
| US 11337927 | use U-3226 | 17 Jan 2034 |
| US 11337927 | use U-3228 | 17 Jan 2034 |
| US 11337927 | use U-3227 | 17 Jan 2034 |
| US 10874616 | product | 14 Nov 2033 |
| US 11576864 | use U-3230 | 14 Nov 2033 |
| US 11576864 | use U-3227 | 14 Nov 2033 |
| US 11576864 | use U-3228 | 14 Nov 2033 |
| US 11576864 | use U-3226 | 14 Nov 2033 |
| US 11576865 | product, use U-3227 | 14 Nov 2033 |
| US 11576865 | product, use U-3228 | 14 Nov 2033 |
| US 11576865 | product, use U-3230 | 14 Nov 2033 |
| US 11576865 | product, use U-3226 | 14 Nov 2033 |
| US 11896717 | product, use U-3228 | 14 Nov 2033 |
| US 11896717 | product, use U-3226 | 14 Nov 2033 |
| US 11896717 | product, use U-3230 | 14 Nov 2033 |
| US 11896717 | product, use U-3227 | 14 Nov 2033 |
| US 10016429 | — | 12 Dec 2028 |
| US 11213528 | — | 12 Dec 2028 |
| US 8722693 | — | 12 Dec 2028 |
| US 8822481 | — | 12 Dec 2028 |
| US 8829013 | — | 12 Dec 2028 |
| US 7598257 | — | 24 Jun 2028 |
| US 8415362 | — | 24 Jun 2028 |
| US 10016429 | use U-3226 | 12 Jun 2028 |
| US 10016429 | use U-3230 | 12 Jun 2028 |
| US 11213528 | product | 12 Jun 2028 |
| US 8722693 | substance, product | 12 Jun 2028 |
| US 8822481 | use U-3227 | 12 Jun 2028 |
| US 8822481 | use U-3228 | 12 Jun 2028 |
| US 8822481 | use U-3230 | 12 Jun 2028 |
| US 8822481 | use U-3226 | 12 Jun 2028 |
| US 8829013 | use U-3227 | 12 Jun 2028 |
| US 8829013 | use U-3228 | 12 Jun 2028 |
| US 7598257 | substance, product, use U-3228 | 24 Dec 2027 |
| US 7598257 | substance, product, use U-3227 | 24 Dec 2027 |
| US 8415362 | substance, product | 24 Dec 2027 |
| US 11744832 | use U-3230 | 12 Dec 2026 |
| US 11744832 | use U-3226 | 12 Dec 2026 |
| US 8530485 | product | 12 Dec 2026 |
| US 9079912 | use U-3226 | 12 Dec 2026 |
| US 9079912 | use U-3228 | 12 Dec 2026 |
| US 9079912 | use U-3227 | 12 Dec 2026 |
| US 9079912 | use U-3230 | 12 Dec 2026 |
| US 9206187 | use U-3227 | 12 Dec 2026 |
| US 9206187 | use U-3228 | 12 Dec 2026 |
| US 9814722 | use U-3230 | 12 Dec 2026 |
| US 9814722 | use U-3226 | 12 Dec 2026 |
Exclusivities · 2 unexpired
| PED | pediatric (6 months added) | 22 Mar 2029 |
| ODE* | 22 Sep 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217180 · 001 · RLD | tablet, extended release, oral | EQ 11MG BASE | 17 Jul 2034 |
| 217180 · 002 · RLD | tablet, extended release, oral | EQ 22MG BASE | 17 Jul 2034 |
| 217180 · 003 · RLD | tablet, extended release, oral | EQ 33MG BASE | 17 Jul 2034 |
| 217180 · 004 · RLD | tablet, extended release, oral | EQ 44MG BASE | 17 Jul 2034 |
| 217180 · 005 · RLD | tablet, extended release, oral | EQ 55MG BASE | 17 Jul 2034 |